Related Experiment Video
Updated: Oct 12, 2025

09:11
Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
Published on: November 23, 2019
6.8K
DNAzyme-Amplified Label-Free Biosensor for the Simple and Sensitive Detection of Pyrophosphatase
Cheng-Yu Lee1, Chi-Hsiang Liao1, Nei-Mei Fang1
1Department of Applied Chemistry, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.
Biosensors
|November 25, 2021
Summary
This study introduces a novel DNAzyme biosensor for detecting pyrophosphatase (PPase) activity. This sensitive and rapid method enables easier clinical diagnosis of diseases linked to PPase levels.
Area of Science:
- Biochemistry
- Analytical Chemistry
- Biotechnology
Background:
- Pyrophosphatase (PPase) is a potential biomarker for various cancers and hyperthyroidism.
- Current PPase detection methods are complex, time-consuming, and lack sensitivity for early clinical diagnosis.
Purpose of the Study:
- To develop a sensitive and efficient DNAzyme-based biosensor for pyrophosphatase (PPase) detection.
- To overcome the limitations of existing methods for PPase analysis in clinical settings.
Main Methods:
- A DNAzyme-based fluorescent biosensor was engineered utilizing a specific substrate with an embedded fluorophore (ATMND).
- PPase activity triggers the cleavage of the DNAzyme/substrate complex, releasing the quenched fluorophore and restoring fluorescence.
- The released ATMND fluorescence intensity directly correlates with PPase activity.
Main Results:
- The developed biosensor demonstrated high sensitivity for PPase detection, with a lowest detectable concentration of 0.5 mU.
- The assay exhibited a wide linear range (0.5–1000 mU), suitable for quantitative analysis.
- The biosensor offers a single-step operation, enhancing its practicality for diagnostics.
Conclusions:
- This DNAzyme-amplified fluorescent biosensor provides a sensitive, rapid, and user-friendly platform for PPase activity detection.
- The developed method has the potential to significantly improve early clinical diagnosis for conditions associated with altered PPase levels.

